The stock will trade on CHAPTER-3 data timing (3Q2026) and NDA submission progress (1H2026). The $132M raise removes near-term dilution risk but signals capital needs. Monitor for any pre-announcement or regulatory updates on the NDA filing.
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 13 $32.94entry
- T+1 · 6mo ago 0.00%α +0.00% · $32.94
- T+5 · 6mo ago −12.11%α −10.95% · $28.95
- T+20 · 5mo ago −2.25%α −1.63% · $32.20
- T+60 · 3mo ago +5.98%α +1.54% · $34.91
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pharvaris reported Q1 2026 EPS of €-0.59 (IFRS), a narrower loss vs €-0.85 a year ago, with cash of €247M extended by a $132M offering into 2028. The key catalysts are the CHAPTER-3 Phase 3 HAE prophylaxis data due in 3Q2026 and the NDA submission for deucrictibant IR in 1H2026.
Key Financial Metrics
Key Facts
- Q1 2026 loss per share €-0.59 vs €-0.85 YoY (IFRS basis)
- Cash and equivalents €247M as of March 31, 2026, down from €292M at Dec 31, 2025
- Closed $132.3M underwritten offering post-quarter, extending cash runway into 2028
- CHAPTER-3 Phase 3 topline data for deucrictibant XR expected in 3Q2026
- NDA submission for deucrictibant IR on track for 1H2026
- R&D expenses €29.9M (Q1 2026) vs €30.9M (Q1 2025); G&A €14.0M vs €11.3M
- No revenue reported; pre-revenue biotech
Financial Impact
No revenue; operating loss €43.9M (R&D + G&A) vs €42.2M YoY. Cash burn rate ~€45M/quarter, extended by $132M offering.
Risk Factors
- CHAPTER-3 Phase 3 failure would significantly impair pipeline value
- Regulatory delays or rejection of deucrictibant IR NDA
- Cash runway depends on no major cost overruns; further dilution possible if milestones slip
- Competition from existing HAE therapies (Takhzyro, Orladeyo, Kalbitor)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293384 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers